Drug Search Results
More Filters [+]

Methylprednisolone aceponate

Alternative Names: methylprednisolone aceponate
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Chile | Colombia | Cyprus | Czech | Dominican Republic | Egypt | Estonia | Finland | Greece | Hong Kong | Hungary | India | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: LEO Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Methylprednisolone aceponate

Countries in Clinic: Germany

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Dermatitis, Atopic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

19-02/MPA-S

P1

Unknown Status

Dermatitis, Atopic

2025-12-31

22-01/MPA-C

P3

Unknown Status

Dermatitis, Atopic

2025-04-26

2019-002686-35

P3

Active, not recruiting

Dermatitis, Atopic

2023-06-07

Recent News Events